SCHEMBL6693243

SCHEMBL6693243

NC(=O)c1cccc2c1c1c(O)cccc1n2Cc1ccccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
LMNA P02545 1/20 0.45
MAP3K14 Q99558 1/20 0.45
PLA2G2A P14555 2/20 0.44
ADRA1D P25100 1/20 0.44
TNF P01375 3/20 0.44
NOD2 Q9HC29 2/20 0.44
NOD1 Q9Y239 2/20 0.44
GAA P10253 1/20 0.42
GFER P55789 1/20 0.42
KDM4E B2RXH2 2/20 0.41
F10 P00742 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6776472 0.88 PLA2G2A (0.44) ALDH1A1MEN1KMT2ALMNAMAP3K14
SCHEMBL6776614 0.88 PLA2G2A (0.44) ALDH1A1MEN1KMT2ALMNAMAP3K14
SCHEMBL6691708 0.87 LMNA (0.48) ALDH1A1MEN1KMT2ALMNAPLA2G2A
SCHEMBL30409640 0.86 PLA2G2A (0.48) ALDH1A1MEN1KMT2ALMNAMAP3K14
SCHEMBL29029759 0.86 PLA2G2A (0.48) ALDH1A1MEN1KMT2ALMNAMAP3K14
SCHEMBL6777226 0.86 ADRA1D (0.43) ALDH1A1MEN1KMT2ALMNAMAP3K14
SCHEMBL6771810 0.86 ALDH1A1 (0.42) ALDH1A1MEN1KMT2ALMNAMAP3K14
SCHEMBL6688455 0.85 MAPT (0.48) ALDH1A1MEN1KMT2ALMNAPLA2G2A
SCHEMBL6693619 0.85 ALDH1A1 (0.47) ALDH1A1KMT2ALMNAPLA2G2ANOD2
SCHEMBL6774411 0.85 AURKA (0.41) ALDH1A1MEN1KMT2APLA2G2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0952149-B1 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors LILLY CO ELI (US) 2004-06-09 EP disclosed
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed